Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bug

Showing results (211-220 of 319) with videos related to

Pageof 32
Sort By:
Cancers|September 27, 2025
First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid NeoplasmsSimone Thomas, Martin Wermke, Vladan Vučinić, et al.
Leukemia|October 7, 2025
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trialInga Hund, Maria Elena Hess, Geoffroy Andrieux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2026
First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in LeukemiaEva Rettinger, Dirk Heckl, Martin Hutter, et al.
Leukemia|August 30, 2012
Analysis of NUP98/NSD1 translocations in adult AML and MDS patientsF Thol, B Kölking, I H I Hollink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2023
Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working PartyAli Bazarbachi, Myriam Labopin, Tobias Gedde-Dahl, et al.
Blood|March 23, 2006
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantationChristoph Schmid, Michael Schleuning, Rainer Schwerdtfeger, et al.
Bone Marrow Transplantation|May 29, 2025
Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the ALWP /EBMTArnon Nagler, Allain-Thibeault Ferhat, Sarah Kayser, et al.
Oncogene|April 29, 2009
Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndromeS Boehrer, L Adès, N Tajeddine, et al.
Oncology Research and Treatment|January 10, 2024
Management of Patients Undergoing CAR-T Cell Therapy in GermanyOlaf Penack, Peter Dreger, Salem Ajib, et al.
Blood|March 6, 2012
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromesFelicitas Thol, Sofia Kade, Carola Schlarmann, et al.
Pageof 32

Showing results (211-220 of 319) with videos related to

Sort By:
Pageof 32
Cancers|September 27, 2025
First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid NeoplasmsSimone Thomas, Martin Wermke, Vladan Vučinić, et al.
Leukemia|October 7, 2025
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trialInga Hund, Maria Elena Hess, Geoffroy Andrieux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2026
First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in LeukemiaEva Rettinger, Dirk Heckl, Martin Hutter, et al.
Leukemia|August 30, 2012
Analysis of NUP98/NSD1 translocations in adult AML and MDS patientsF Thol, B Kölking, I H I Hollink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2023
Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working PartyAli Bazarbachi, Myriam Labopin, Tobias Gedde-Dahl, et al.
Blood|March 23, 2006
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantationChristoph Schmid, Michael Schleuning, Rainer Schwerdtfeger, et al.
Bone Marrow Transplantation|May 29, 2025
Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the ALWP /EBMTArnon Nagler, Allain-Thibeault Ferhat, Sarah Kayser, et al.
Oncogene|April 29, 2009
Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndromeS Boehrer, L Adès, N Tajeddine, et al.
Oncology Research and Treatment|January 10, 2024
Management of Patients Undergoing CAR-T Cell Therapy in GermanyOlaf Penack, Peter Dreger, Salem Ajib, et al.
Blood|March 6, 2012
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromesFelicitas Thol, Sofia Kade, Carola Schlarmann, et al.
Pageof 32